What Does the Washington Warning Mean for Ozempic Users?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Safety Surveillance

If you take Ozempic and have persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. Decades of pharmacovigilance have established that delayed gastric emptying can occur with certain medications, and recent reports have raised specific questions about GLP-1 receptor agonists. This page explains what the Washington warning means in practical terms and what you should know.

Understanding Ozempic and Its Gastrointestinal Risks

Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, is prescribed for glycemic control in type 2 diabetes. However, its use has been associated with significant gastrointestinal adverse effects, including gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. This section examines the clinical presentation of gastroparesis, Ozempic's pharmacological profile, reported adverse effects, mechanistic pathways linking the drug to gastroparesis, adequacy of warnings, settlement considerations, and the timeline between exposure and harm. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate of solid food emptying from the stomach. The condition can lead to malnutrition, weight loss, and impaired quality of life. In the context of Ozempic, gastrointestinal adverse reactions are well-documented. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0% placebo, 2.7% 0.5 mg, 1.1% 1 mg), flatulence (0.8% placebo, 0.4% 0.5 mg, 1.5% 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% 0.5 mg, 1.5% 1 mg), and gastritis (0.8% placebo, 0.8% 0.5 mg, 0.4% 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which may include gastroparesis.

Mechanisms Linking Ozempic to Gastroparesis and Legal Implications

The pharmacology of Ozempic involves activation of GLP-1 receptors, which slow gastric emptying and reduce postprandial glucose excursions. This mechanism is intended to improve glycemic control but can also lead to delayed gastric emptying, a hallmark of gastroparesis. Mechanistically, GLP-1 receptor agonists like Ozempic inhibit gastric motility through vagal and enteric nervous system pathways, potentially causing prolonged gastric retention. While the label does not explicitly list gastroparesis as an adverse reaction, the reported gastrointestinal effects—nausea, vomiting, dyspepsia, and gastroesophageal reflux disease—are consistent with gastroparesis symptoms. The label notes that serious hypersensitivity reactions, such as anaphylaxis and angioedema, have been reported, but these are distinct from gastrointestinal effects (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific gastroparesis warning raises questions about the adequacy of risk communication. Regarding risk anchors, the adequacy of warnings is a critical issue. The Ozempic label includes warnings about gastrointestinal adverse reactions but does not specifically mention gastroparesis. This omission may affect patients' ability to recognize early symptoms and seek timely medical intervention. For affected patients, settlement considerations involve documenting the link between Ozempic use and gastroparesis diagnosis, including the timeline of exposure. The timeline between exposure and documented harm is often during dose escalation, as most gastrointestinal reactions occur in this period. Patients who develop persistent symptoms after starting Ozempic may have a basis for legal claims if they can demonstrate that the drug caused or contributed to their condition. Settlement-related considerations include the severity of gastroparesis, duration of treatment, and whether alternative causes were ruled out. In summary, Ozempic is associated with a range of gastrointestinal adverse reactions, including those consistent with gastroparesis. The clinical presentation of gastroparesis overlaps with common side effects like nausea and vomiting, making diagnosis challenging. Mechanistically, GLP-1 receptor agonists slow gastric emptying, which can lead to gastroparesis. The adequacy of warnings is questionable, as the label does not explicitly address gastroparesis. For patients considering legal action, documenting the timeline of exposure and harm is essential. This narrative is based solely on the provided evidence. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it related to Ozempic?

Gastroparesis is a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms like nausea, vomiting, early satiety, and abdominal pain. Ozempic, a GLP-1 receptor agonist, slows gastric emptying as part of its mechanism, which can cause or exacerbate gastroparesis. Clinical trials show dose-dependent gastrointestinal adverse reactions, including nausea and vomiting, which are consistent with gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label warn about gastroparesis?

The Ozempic label does not explicitly list gastroparesis as an adverse reaction, though it warns about gastrointestinal side effects such as nausea, vomiting, and diarrhea. The absence of a specific gastroparesis warning may affect patients' ability to recognize early symptoms and seek timely medical intervention (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What should I do if I developed gastroparesis after taking Ozempic?

If you developed gastroparesis after taking Ozempic, it is important to document your exposure timeline and seek medical evaluation. You may be eligible for legal review to determine if your condition is linked to the medication. Contact a qualified attorney specializing in pharmaceutical injury to discuss your case and potential settlement options.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.